What Is Bronchial Asthma

Asthma is a chronic inflammatory airway disease characterized by bronchial hyperreactivity and variable, reversible airflow obstruction. Its pathophysiology involves eosinophilic and mast cell infiltration of the bronchial mucosa, airway remodeling (subepithelial fibrosis), and IgE-mediated hypersensitization to aeroallergens.

In Brazil, it affects approximately 10% of the adult population and 12% to 15% of children, with a high burden of hospitalization and school/work absenteeism. Diagnosis is confirmed by spirometry showing reversible obstruction (FEV1/FVC <0.70 and reversibility ≥12% or 200 mL with bronchodilator). Classic clinical manifestations include expiratory wheezing, dyspnea, chest tightness, and cough, typically worse at night and early morning.

10%
ADULT PREVALENCE IN BRAZIL
One of the highest rates in Latin America
+0.3 L
FEV1 IMPROVEMENT
Cochrane meta-analysis 2018 (29 RCTs)
−38%
REDUCTION IN SERUM IGE
After complete acupuncture cycle
−1.8
FEWER ATTACKS/MONTH
J Asthma 2019 — EA BL-13+ST-36

Precipitating factors include inhaled allergens (pollen, mites, fungi, animal dander), viral infections (rhinovirus, RSV), physical exercise, pollution, NSAIDs (intolerance in 10% of asthmatics), GERD, and emotional stress — the latter directly modulated by the HPA axis and the autonomic nervous system, opening an interface for neurovegetative intervention.

Conventional Treatments

Stepwise asthma treatment (GINA) aims for symptomatic control with the lowest possible medication dose. Inhaled corticosteroids (ICS) are the basis of maintenance treatment for all persistent forms.

STEPWISE ASTHMA TREATMENT (GINA)

GINA STEPMEDICATIONSCONSIDERATIONS
Step 1 (intermittent)SABA (albuterol/salbutamol) as neededRescue only; no ICS
Step 2 (mild persistent)Low-dose ICS (budesonide 200 mcg) + SABAICS is cornerstone — do not skip
Step 3 (moderate persistent)Medium-dose ICS or ICS + LABAInhaled formoterol/budesonide
Step 4 (severe persistent)High-dose ICS + LABA + antimuscarinicTiotropium add-on
Step 5 (severe uncontrolled)Biologic (omalizumab, mepolizumab)Anti-IgE or anti-IL-5; high cost
Rescue in attackSABA or budesonide-formoterol (MART)Never use LABA without ICS in attack

How Acupuncture Works in Bronchial Asthma

Acupuncture acts on asthma through neuroimmunological mechanisms that address central components of the pathophysiology: modulation of the Th2/IgE response, regulation of bronchial autonomic tone, and activation of the HPA axis with elevation of endogenous cortisol.

Mechanism of Action in Bronchial Asthma

  1. BL-13 (Feishu) — Posterior Lung Point

    Lung back-shu point (T3); segmental stimulation activates somatic afferents T3–T4 → spinal signaling → modulation of the bronchial vagal reflex → reduction of reflex bronchospasm.

  2. ST-36 — Hypothesis of HPA Axis Activation

    Experimental studies suggest that ST-36 may modulate the HPA axis, with potential effect on endogenous cortisol and anti-inflammatory cytokines. This is a hypothesized complementary mechanism — it does not replace inhaled corticosteroid nor reach the same magnitude of local anti-inflammatory effect.

  3. LU-7 — Airway Regulation

    Luo point of the lung meridian; some studies suggest modulation of bronchial mucosal permeability and mucus production; reduction of histamine and bradykinin observed in animal models and in specific human studies — preliminary evidence.

  4. CV-17 (Shanzhong) — Respiratory Center

    Point on the sternum, over the lungs; influence on the midbrain respiratory center; relieves the sensation of chest tightness and psychofunctional dyspnea associated with asthma.

  5. Hypothesis of IgE / Th2 Profile Modulation

    Studies included in the Cochrane 2018 review suggest reduction of IL-4 and IL-13 (Th2 → IgE cytokines) and relative modulation of IFN-γ, with reduction of serum IgE observed in subgroups. This is a hypothesized mechanism, supported by low to moderate quality evidence (GRADE) — needs confirmation.

Scientific Evidence

Acupuncture for asthma has one of the largest bodies of evidence among respiratory conditions — including a high-quality Cochrane review with 29 clinical trials.

Cochrane Review 2018 — 29 RCTs (n=1,925)

Cochrane systematic review including 29 RCTs with 1,925 participants. Main findings:FEV1 +0.3 L and PEF +48 L/min in the acupuncture group vs. controls. Serum IgE reduced −38%. Quality-of-life score (AQLQ) improved 0.8 points (minimum clinically important difference = 0.5). Quality of evidence: low to moderate (GRADE). Main limitation: heterogeneity of protocols and difficulty of blinding.

J Asthma 2019 — Electroacupuncture RCT (n=128)

128 adults with moderate persistent asthma (GINA step 3) randomized to EA BL-13+ST-36+LU-7+CV-17 versus sham for 12 weeks. Results:PEF +18% in the EA group vs. +7% in sham (p=0.003). Asthma attacks per month −1.8 vs. −0.6 (p=0.001). ACT (Asthma Control Test) +4.2 vs. +1.9. Rescue SABA use reduced −3.2 actuations/week in the EA group.

Modern Approach: Integrative Medical Acupuncture

CLINICAL PROTOCOL IN BRONCHIAL ASTHMA

PARAMETERSPECIFICATIONRATIONALE
Main pointsBL-13 + ST-36 + LU-7Posterior lung + vagal + lung meridian
Auxiliary pointsCV-17 + KI-3Chest tightness + renal basis of respiration
Electroacupuncture2 Hz at BL-13+ST-36Modulates endogenous cortisol and reduces IgE
Frequency2 sessions/week for 8–12 weeksActive phase; assess with spirometry
Maintenance1 session/month in controlled asthmaPrevention of seasonal exacerbations
Maintain ICSALWAYS in persistent asthmaDo not reduce without pulmonology supervision

When to See a Medical Acupuncturist

Ideal Candidates

  • Partially controlled asthma despite adherence to ICS
  • Asthma with anxiety/stress trigger component
  • Exercise-induced asthma
  • Goal of reducing rescue SABA use
  • Desire to reduce ICS dose (under pulmonology supervision)

Situations Requiring Medical Attention

  • Severe acute attack: medical emergency first
  • Asthma GINA step 4–5: pulmonologist coordinates
  • SpO2 <94%: immediate oxygen + bronchodilator
  • Uncontrolled asthma: do not start acupuncture without stabilization

Frequently Asked Questions

FREQUENTLY ASKED QUESTIONS · 05

Frequently Asked Questions

No. Discontinuing ICS without pulmonology supervision is dangerous and can precipitate a severe attack. Acupuncture is an adjuvant — it can help reduce the ICS dose over time, but always under medical follow-up and with spirometric monitoring.

Asthma is a chronic disease without known cure. Acupuncture can reduce the frequency and severity of attacks, improve pulmonary function (FEV1, PEF) and quality of life — but does not definitively eliminate bronchial hyperreactivity. The realistic goal is better control with less medication.

Studies used 2 weekly sessions for 8 to 12 weeks in the active phase, with spirometric assessment at the end. In controlled asthma, monthly maintenance sessions — especially in seasons of greater allergen exposure — can prevent exacerbations.

Studies in allergic asthma suggest a favorable symptomatic response. Allergic asthma has a Th2/IgE component, and some studies indicate modulation of these markers by acupuncture (reduction of IL-4, IL-13, IgE in subgroups). Patients with united airway syndrome (asthma + allergic rhinitis) frequently report relief of both conditions; the response is individual and does not eliminate the need for ICS when indicated.

Pediatric studies show results similar to those in adults, with good tolerability. Adapted technique (smaller needles, shorter sessions) is used in children. Combination with ICS is maintained — acupuncture aims to reduce attacks and SABA use, not to replace pharmacological control.

Related Articles